Oral rivaroxaban for symptomatic venous thromboembolism Einstein Investigators New England Journal of Medicine 363 (26), 2499-2510, 2010 | 3903 | 2010 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism EPE Investigators N Engl j Med 2012 (366), 1287-1297, 2012 | 2885* | 2012 |
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation J Steffel, P Verhamme, TS Potpara, P Albaladejo, M Antz, L Desteghe, ... European heart journal 39 (16), 1330-1393, 2018 | 2459 | 2018 |
Rivaroxaban with or without aspirin in stable cardiovascular disease JW Eikelboom, SJ Connolly, J Bosch, GR Dagenais, RG Hart, ... New England Journal of Medicine 377 (14), 1319-1330, 2017 | 2406 | 2017 |
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism Hokusai-VTE Investigators New England journal of medicine 369 (15), 1406-1415, 2013 | 2207 | 2013 |
Idarucizumab for dabigatran reversal CV Pollack Jr, PA Reilly, J Eikelboom, S Glund, P Verhamme, ... New England Journal of Medicine 373 (6), 511-520, 2015 | 2044 | 2015 |
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, HC Diener, W Hacke, ... Ep Europace 17 (10), 1467-1507, 2015 | 1753 | 2015 |
Edoxaban for the treatment of cancer-associated venous thromboembolism GE Raskob, N Van Es, P Verhamme, M Carrier, M Di Nisio, D Garcia, ... New England Journal of Medicine 378 (7), 615-624, 2018 | 1647 | 2018 |
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... Europace 15 (5), 625-651, 2013 | 1268 | 2013 |
Idarucizumab for dabigatran reversal—full cohort analysis CV Pollack Jr, PA Reilly, J Van Ryn, JW Eikelboom, S Glund, ... New England Journal of Medicine 377 (5), 431-441, 2017 | 1194 | 2017 |
Andexanet alfa for acute major bleeding associated with factor Xa inhibitors SJ Connolly, TJ Milling Jr, JW Eikelboom, CM Gibson, JT Curnutte, A Gold, ... New England Journal of Medicine 375 (12), 1131-1141, 2016 | 940 | 2016 |
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial SS Anand, J Bosch, JW Eikelboom, SJ Connolly, R Diaz, P Widimsky, ... The Lancet 391 (10117), 219-229, 2018 | 938 | 2018 |
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors SJ Connolly, M Crowther, JW Eikelboom, CM Gibson, JT Curnutte, ... New England Journal of Medicine 380 (14), 1326-1335, 2019 | 871 | 2019 |
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism TL Ortel, I Neumann, W Ageno, R Beyth, NP Clark, A Cuker, BA Hutten, ... Blood advances 4 (19), 4693-4738, 2020 | 859 | 2020 |
Rivaroxaban or aspirin for extended treatment of venous thromboembolism JI Weitz, AWA Lensing, MH Prins, R Bauersachs, J Beyer-Westendorf, ... New England Journal of Medicine 376 (13), 1211-1222, 2017 | 814 | 2017 |
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial D Aujesky, PM Roy, F Verschuren, M Righini, J Osterwalder, M Egloff, ... The Lancet 378 (9785), 41-48, 2011 | 711 | 2011 |
Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease P Holvoet, A Mertens, P Verhamme, K Bogaerts, G Beyens, R Verhaeghe, ... Arteriosclerosis, thrombosis, and vascular biology 21 (5), 844-848, 2001 | 694 | 2001 |
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary H Heidbuchel, P Verhamme, M Alings, M Antz, W Hacke, J Oldgren, ... European heart journal 34 (27), 2094-2106, 2013 | 570 | 2013 |
Factor XI antisense oligonucleotide for prevention of venous thrombosis HR Büller, C Bethune, S Bhanot, D Gailani, BP Monia, GE Raskob, ... New England Journal of Medicine 372 (3), 232-240, 2015 | 564 | 2015 |
Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines Z Zhai, C Li, Y Chen, G Gerotziafas, Z Zhang, J Wan, P Liu, I Elalamy, ... Thrombosis and haemostasis 120 (06), 937-948, 2020 | 429 | 2020 |